These evidence shows FFAR3 signaling similar to FFAR2 is a promising therapeutic target for treating gut related disorders such as obesity, T2D, colitis and diarrhea, by honing gut-hormonal synthesis and balancing the microbiome-gut-brain axis (Table 3). This evidence concerns the gene FFAR3 and type 2 diabetes mellitus.